Corcept Therapeutics Inc
SWB:HTD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Corcept Therapeutics Inc
SWB:HTD
|
US |
|
Heineken Holding NV
F:4H50
|
NL |
|
B
|
Bertrandt AG
XMUN:BDT
|
DE |
|
Equinor ASA
OSE:EQNR
|
NO |
|
M
|
Metro AG
DUS:B4B3
|
DE |
|
Cantaloupe Inc
F:UTE0
|
US |
|
V
|
Volvo AB
XMUN:VOL3
|
SE |
|
M
|
Mayr Melnhof Karton AG
XMUN:MYM
|
AT |
|
Peab AB
F:PEKB
|
SE |
|
A
|
Axon Enterprise Inc
SWB:TCS
|
US |
|
Soditech SA
PAR:ALSEC
|
FR |
|
F
|
Fresenius SE & Co KGaA
F:FRE
|
DE |
Wall St Price Targets
HTD Price Targets Summary
Corcept Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for HTD is 57.08 EUR with a low forecast of 36.9 EUR and a high forecast of 95.89 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is HTD's stock price target?
Price Target
57.08
EUR
According to Wall Street analysts, the average 1-year price target for HTD is 57.08 EUR with a low forecast of 36.9 EUR and a high forecast of 95.89 EUR.
What is the Revenue forecast for Corcept Therapeutics Inc?
Projected CAGR
17%
Over the last 13 years, the compound annual growth rate for Revenue has been 52%. The projected CAGR for the next 8 years is 17%.
What is the Operating Income forecast for Corcept Therapeutics Inc?
Projected CAGR
58%
The compound annual growth rate for Operating Income over the next 8 years is 58%.
What is the Net Income forecast for Corcept Therapeutics Inc?
Projected CAGR
36%
The compound annual growth rate for Net Income over the next 8 years is 36%.
